Immunocore Holdings plc has reported an estimated 70% two-year overall survival rate among 17 evaluable first-line patients with HLA-A*02:01-positive metastatic uveal melanoma treated with investigational brenetafusp plus Kimmtrak, or tebentafusp-tebn. Median overall survival had not been reached after a median follow-up of 29 months, while the combination produced a 29% objective response rate, a 71% disease control rate, median progression-free survival of 8.1 months and median duration of response of 24.1 months.
The results, presented around the 2026 Society for Immunotherapy of Cancer Annual Meeting, provide an early clinical signal for Immunocore’s strategy of combining two engineered T-cell receptor therapies that recognise different tumour-associated targets. Immunocore believes these are the first data to show clinical activity with a combination of two T-cell engagers in a solid tumour, although that description relates to the treatment strategy rather than evidence that the regimen is superior to established therapy.
The distinction is particularly important because the efficacy analysis involves only 17 evaluable first-line patients and does not include a randomised contemporaneous control group. Immunocore is responding to that limitation by planning DUET-UVEAL, a randomised Phase 2/3 study intended to determine whether adding brenetafusp to Kimmtrak produces a clinically meaningful advantage in unresectable or metastatic uveal melanoma.
Investor attention increased after the clinical disclosure and Immunocore’s third-quarter update. IMCR closed November 6 at $30.99, up 9.1% for the session, with approximately 1.5 million shares traded. The move coincided with both new brenetafusp data and financial results, so the share-price reaction is better viewed as a broader reassessment of Immunocore’s commercial and clinical pipeline rather than evidence that investors were valuing one dataset in isolation.
Why does a 70% two-year survival estimate stand out in metastatic uveal melanoma?
Metastatic uveal melanoma has historically been one of the more difficult melanoma subtypes to treat once disease spreads beyond the eye, particularly because its biology differs substantially from cutaneous melanoma. The liver is a common site of metastasis, and conventional immune checkpoint inhibitors that transformed treatment for several other melanomas have generally produced more limited activity in this disease.
Kimmtrak changed the treatment landscape by becoming the first systemic therapy to demonstrate a randomised overall survival benefit in HLA-A*02:01-positive metastatic uveal melanoma. In its pivotal Phase 3 programme, two-year overall survival was 45% with tebentafusp compared with 30% among patients receiving investigator-selected control therapy, while median overall survival was 21.7 months versus 16.0 months in the primary analysis.
Against that background, the 70% estimated two-year survival rate reported with brenetafusp plus Kimmtrak is clinically interesting. It would nevertheless be inappropriate to conclude that the combination improves survival over Kimmtrak alone because the figures come from different trials with substantially different sample sizes, enrolment periods, patient characteristics and other potential sources of bias.
The original Kimmtrak trial randomised hundreds of patients, whereas the new combination survival estimate is based on 17 evaluable first-line patients. A few unusually favourable or unfavourable outcomes can materially alter percentages in such a small cohort, which is why the planned randomised DUET-UVEAL trial will carry considerably more evidentiary weight than the current cross-trial numerical comparison.
What did the Phase 1/2 brenetafusp and Kimmtrak cohort actually show?
As of the June 2026 data cut-off, 26 adults with metastatic uveal melanoma had received clinically active doses of brenetafusp plus Kimmtrak, while another 22 had received brenetafusp monotherapy. The first-line efficacy analysis that generated the strongest survival signal focused on 17 evaluable combination-treated patients.
Five of those 17 patients achieved an objective response, producing the reported 29% response rate, while disease control was observed in 71%. Median progression-free survival reached 8.1 months and median duration of response was 24.1 months, suggesting that responses in the small number of responding patients could be sustained for a meaningful period.
The survival data generated the greatest attention. Median overall survival had not been reached after a median 29 months of follow-up, 10 of the 17 patients remained on study at the data cut-off, and estimated survival was 88% at one year and 70% at two years. Immunocore also reported that most patients surviving beyond two years had received only the combination rather than subsequent systemic therapy, an exploratory observation intended to support the possibility that the regimen itself contributed materially to the outcomes.
These figures remain preliminary Phase 1/2 evidence rather than confirmatory efficacy data. The absence of randomisation makes it impossible to exclude the influence of baseline prognosis, patient selection and other post-treatment factors, while survival estimates will continue to evolve as follow-up matures and additional events occur.
Why is combining gp100 and PRAME-targeted T-cell engagers scientifically interesting?
Kimmtrak and brenetafusp both originate from Immunocore’s ImmTAC platform, which uses engineered soluble T-cell receptors designed to recognise specific peptide fragments presented on tumour cells and redirect the patient’s own T cells toward those cells. The approach differs from conventional antibody-based checkpoint inhibition because it can target intracellular proteins when fragments of those proteins are presented at the tumour-cell surface through the human leukocyte antigen system.
Kimmtrak targets a peptide derived from gp100 in the context of HLA-A02:01 and is already approved for HLA-A02:01-positive adults with unresectable or metastatic uveal melanoma. Brenetafusp is investigational and targets PRAME, a cancer-associated antigen expressed across several tumour types, also through an HLA-A*02:01-restricted engineered T-cell receptor.
Combining the two agents is intended to expose the tumour to immune pressure against two separate cancer-associated targets. In principle, broader antigen targeting could reduce dependence on uniform expression of a single target and might improve the depth or persistence of tumour control, although the current study was not designed to establish biological synergy.
That distinction will become critical as development progresses. Showing that two active agents can be administered together and produce responses is different from demonstrating that the combination creates incremental benefit beyond Kimmtrak alone. DUET-UVEAL will therefore need a comparator capable of answering whether PRAME-directed brenetafusp adds enough efficacy to justify additional treatment complexity and risk.
Why does the 29% response rate need to be interpreted differently in uveal melanoma?
Objective response rate is an important measure of antitumour activity, but Kimmtrak’s development history shows why tumour shrinkage alone does not fully capture the value of T-cell receptor therapy in metastatic uveal melanoma. The approved therapy demonstrated a clear survival benefit in its pivotal randomised study despite a relatively modest conventional response rate.
The brenetafusp combination’s 29% response rate is therefore only one part of the emerging efficacy profile. The 24.1-month median duration of response, 8.1-month median progression-free survival and 70% estimated two-year overall survival provide additional dimensions that may ultimately prove more relevant if confirmed in a larger comparative trial.
Immunocore also reported exploratory circulating tumour DNA results. Among nine evaluable combination-treated patients, eight experienced a ctDNA response and four achieved ctDNA clearance. Those findings may indicate biological activity, but the analysis is based on a very small number of patients and molecular clearance cannot be treated as evidence of survival improvement or disease modification without appropriate clinical validation.
The combination programme will therefore be judged primarily on clinically meaningful outcomes rather than whether one biomarker or response percentage appears favourable. For a disease in which survival has already been improved by Kimmtrak, the development threshold for adding another therapy is necessarily higher than simply demonstrating that the second agent is biologically active.
Can two T-cell engagers be combined without creating unacceptable immune toxicity?
Safety is one of the most important questions surrounding the programme because both medicines activate T cells, creating the possibility that combining them could intensify immune-mediated toxicities. Cytokine release syndrome and rash were the most frequently reported treatment-related adverse events with the combination, occurring in 77% of patients each.
Immunocore reported that cytokine release syndrome events were Grade 1 or Grade 2 and attenuated over time, with no Grade 3 or higher cytokine release syndrome reported in the disclosed combination dataset. Grade 3 or Grade 4 treatment-related adverse events were primarily transient decreases in lymphocyte counts that resolved without intervention, while no treatment-related adverse event led to discontinuation or death.
Those observations support continued clinical development but should not be interpreted as establishing a complete safety profile. Exposure remains limited, and uncommon serious adverse events may only become apparent when substantially more patients receive the regimen. A randomised Phase 2/3 programme will also provide a clearer comparison of treatment burden against the established Kimmtrak safety profile.
Kimmtrak itself carries a boxed warning for cytokine release syndrome and requires intensive monitoring during early doses under its approved U.S. regimen. Adding a second T-cell engager therefore creates a particularly important operational and safety test if the combination eventually progresses toward commercial use.
Why does HLA-A*02:01 still restrict the size of the potential patient population?
Both Kimmtrak and the reported brenetafusp combination rely on the HLA-A*02:01 genetic background because their engineered T-cell receptors recognise tumour peptides only when presented through that specific HLA molecule. Patients must therefore be HLA genotyped before being considered for treatment.
This precision enables the therapies to recognise intracellular cancer-associated proteins, but it also restricts the population that can benefit. Patients who do not carry HLA-A*02:01 are outside Kimmtrak’s approved population and would not fall within the patient group being targeted by the planned DUET-UVEAL combination study.
For Immunocore, this creates both a commercial limitation and a platform-development challenge. Expanding the addressable population over the longer term will require additional candidates capable of recognising tumour targets presented by other common HLA types rather than relying solely on HLA-A*02:01.
Within metastatic uveal melanoma, however, HLA testing is already part of the treatment pathway created by Kimmtrak. That existing clinical infrastructure could make combination adoption more straightforward if brenetafusp eventually demonstrates incremental efficacy and receives regulatory approval, because eligible patients are already being identified through the same fundamental genetic selection process.
Why is Kimmtrak revenue important to Immunocore’s ability to fund the next generation of ImmTAC trials?
Immunocore enters the brenetafusp expansion programme from a stronger financial position than many biotechnology companies moving multiple assets into pivotal development. Kimmtrak generated $102.2 million in third-quarter 2026 net product revenue and $324.8 million during the first nine months of the year, representing 10% growth compared with the corresponding nine-month period of 2025.
The product is approved in 39 countries and has been launched in more than 30, giving Immunocore an established commercial operation and recurring revenue while it funds additional clinical programmes. The company ended September with $901.3 million in cash, cash equivalents and marketable securities.
Research and development expenditure reached $74.7 million during the third quarter as Immunocore advanced three Phase 3 studies and other programmes, while the company reported a quarterly net loss of $14.2 million. That expenditure profile will likely remain substantial as DUET-UVEAL joins an already broad late-stage clinical portfolio.
The financial position does not remove long-term capital requirements, particularly if several programmes succeed simultaneously and require manufacturing or commercial expansion. It does, however, allow Immunocore to pursue a randomised combination strategy without the immediate financing pressure faced by many small oncology developers following an encouraging early-stage readout.
How does DUET-UVEAL fit into Immunocore’s broader melanoma strategy?
The combination programme is only one part of a wider effort to extend Immunocore’s T-cell receptor platform beyond Kimmtrak’s current metastatic uveal melanoma indication. The company has completed target enrolment of 540 patients in TEBE-AM, a Phase 3 study evaluating tebentafusp in previously treated advanced cutaneous melanoma, with topline overall survival results expected in the second quarter of 2027.
Brenetafusp is also being developed independently of the uveal melanoma combination. Immunocore is running the Phase 3 PRISM-MEL-301 study evaluating brenetafusp plus nivolumab in first-line advanced cutaneous melanoma, giving the PRAME-targeted therapy a second major route toward potential regulatory validation.
The portfolio architecture is strategically important. Kimmtrak provides commercial proof that the ImmTAC platform can produce an approved medicine, while TEBE-AM is testing whether tebentafusp can extend beyond uveal melanoma and brenetafusp is testing whether another tumour antigen can independently support late-stage development.
DUET-UVEAL adds another question on top of those programmes: whether two ImmTAC therapies can be combined to improve outcomes beyond a successful single agent. Confirmation would broaden the platform concept from individual targeted T-cell engagers into multi-target regimens, potentially opening a new development model across cancers expressing suitable antigens.
Why did IMCR stock rise, and what should investors watch next?
Immunocore shares closed at $30.99 on November 6, up 9.1% from the previous session, with approximately 1.5 million shares changing hands. The increase followed the clinical disclosure and third-quarter business update, while the stock remained within its 52-week trading range rather than breaking into new highs.
The market reaction is understandable because brenetafusp now has several potential value drivers rather than depending on one indication. The metastatic uveal melanoma combination provides an early survival signal, PRISM-MEL-301 gives brenetafusp a Phase 3 opportunity in advanced cutaneous melanoma, and Kimmtrak continues to generate commercial revenue while supporting the wider platform.
The principal risk is that early-stage combination data can look unusually strong when patient numbers are small. Seventeen evaluable first-line patients are sufficient to generate a hypothesis and justify randomised development, but they are not sufficient to determine whether a 70% two-year survival rate will persist when hundreds of patients are treated under controlled conditions.
DUET-UVEAL will consequently be the decisive test of this particular strategy. If randomised results show that adding PRAME-directed brenetafusp to gp100-directed Kimmtrak produces a meaningful improvement in survival or another clinically important endpoint without disproportionate toxicity, Immunocore could establish a new development model for combining engineered T-cell receptor therapies in solid tumours. If the advantage narrows substantially in a controlled population, the current data will instead be remembered as an encouraging Phase 1/2 signal that required greater evidentiary maturity before its true clinical value could be determined.
